Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Current Assets: 2019-2024

Historic Current Assets for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $619.4 million.

  • Nurix Therapeutics' Current Assets fell 3.39% to $440.6 million in Q3 2025 from the same period last year, while for Aug 2025 it was $440.6 million, marking a year-over-year decrease of 3.39%. This contributed to the annual value of $619.4 million for FY2024, which is 109.60% up from last year.
  • According to the latest figures from FY2024, Nurix Therapeutics' Current Assets is $619.4 million, which was up 109.60% from $295.5 million recorded in FY2023.
  • In the past 5 years, Nurix Therapeutics' Current Assets ranged from a high of $619.4 million in FY2024 and a low of $295.5 million during FY2023.
  • Its 3-year average for Current Assets is $411.1 million, with a median of $318.4 million in 2022.
  • Per our database at Business Quant, Nurix Therapeutics' Current Assets soared by 658.33% in 2020 and then decreased by 7.21% in 2023.
  • Yearly analysis of 5 years shows Nurix Therapeutics' Current Assets stood at $298.4 million in 2020, then rose by 4.25% to $311.1 million in 2021, then climbed by 2.36% to $318.4 million in 2022, then dropped by 7.21% to $295.5 million in 2023, then soared by 109.60% to $619.4 million in 2024.